-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓USDISIN US45845P1084
ISIN US45845P1084
WKN A1J5U0
Symbol ICPT
Währung
USD
Firmenname
Intercept Pharmaceuticals, Inc
Marktkapitalisierung
800.841.280 (+- 29%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
1.030.682.560 oder 571.000.000
Mitarbeiter
462 (+- 26%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
583 oder 341 Mitarbeiter
EBITDA -281.096.992
PEGRatio -0.69
Buchwert 1.569
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 38,15 USD +2,11%
5 ETFs die in Intercept Pharmaceuticals Inc investieren
Dir gefallen die Informationen zu Intercept Pharmaceuticals Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Intercept Pharmaceuticals Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Intercept Pharmaceuticals Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Intercept Pharmaceuticals Inc?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
18 News & Informationen zur Intercept Pharmaceuticals Inc Aktie
Intercept Pharmaceuticals initiates notes exchange, stock buyback (NASDAQ:ICPT)
Biopharmaceutical company Intercept Pharmaceuticals <> has reached an agreement with certain holders of its existing 3.25% Convertible Senior Notes due 2023 and 2.00%…
Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Completed a successful pre-IND meeting with the FDA for VRDN-001, a differentiated monoclonal antibody targeting IGF-1R for the treatment of Thyroid Eye…
Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase
NEW YORK, Aug. 10, 2021 — Intercept Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive… | August 11, 2021
Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) (“Intercept”), a biopharmaceutical company focused on the …
Intercept Pharmaceuticals Inc. Stock Quote (U.S.: Nasdaq)
ICPT | Complete Intercept Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q2 2021 Results – Earnings Call Transcript
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q2 2021 Earnings Conference Call July 29, 2021 8:30 AM ET Company Participants Lisa DeFrancesco – Senior Vice President, Corporate Affairs and…
Intercept Pharmaceuticals, Inc. 2021 Q2 – Results – Earnings Call Presentation (NASDAQ:ICPT)
The following slide deck was published by Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter Company reiterates 2021 financial guidance of…
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was s…
Intercept Pharmaceuticals (ICPT) Investor Presentation – Slideshow (NASDAQ:ICPT)
The following slide deck was published by Intercept Pharmaceuticals, Inc.
Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020
Los Angeles, USA , Jan. 13, 2021 (GLOBE NEWSWIRE) — Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020
NASH Drug Pipeline Shows Promise as …
Stocks That Hit 52-Week Lows On Monday
During Monday’s morning session, 9 stocks hit new 52-week lows.
Points of Interest: The largest company in terms of market cap to set a new …
FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contac
LOS ANGELES, CA / ACCESSWIRE / January 3, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Intercept Pharmaceuticals, Inc.
ICPT Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Intercept Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 4, 2021
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. and certain of its officers, on behalf of shareholders… | January 3, 2021
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ICPT
NEW YORK, Jan. 2, 2021 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ? and certain of its officers.?The class… | January 3, 2021
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Intercept Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern… | January 2, 2021
ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Loss
NEW YORK, Jan. 01, 2021 — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. between September 28, 2019 and October…
ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Loss
NEW YORK, Jan. 01, 2021 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept …